Yes, Sprycel Treats CML
Sprycel (dasatinib) is FDA-approved for chronic myeloid leukemia (CML) in adults and children. It targets the BCR-ABL tyrosine kinase, a protein driving CML cell growth, and is used in chronic, accelerated, or blast phases.[1]
How Sprycel Fits CML Treatment Stages
Sprycel works as a first- or second-line therapy after imatinib (Gleevec) fails. In newly diagnosed chronic-phase CML, it matches or exceeds imatinib in progression-free survival per the DASISION trial (5-year data: 84% major molecular response).[1][2] For resistant or intolerant patients, guidelines from NCCN and ELN recommend it alongside other TKIs like nilotinib or bosutinib.
Sprycel vs. Other CML Drugs
| Drug | Key Use in CML | Response Rates (Chronic Phase) | Common Resistance Mechanism |
|------|----------------|-------------------------------|-----------------------------|
| Sprycel (dasatinib) | 1st/2nd line | ~70-80% major cytogenetic response [2] | BCR-ABL mutations (e.g., T315I less common than with imatinib) |
| Gleevec (imatinib) | 1st line standard | 65-80% [1] | T315I, F317L |
| Tasigna (nilotinib) | 1st/2nd line | Similar to Sprycel [3] | T315I frequent |
| Bosulif (bosutinib) | 2nd/3rd line | Lower in later lines [3] | Various kinase domain mutations |
Sprycel stands out for pleural effusion risk but better CNS penetration in blast crisis.
Common Side Effects Patients Report
Myelosuppression (low blood counts), diarrhea, headache, and pleural effusion (fluid around lungs, ~25% incidence). Fluid retention prompts monitoring; severe cases need dose cuts or discontinuation.[1] Long-term: pulmonary hypertension rare but serious.
Who Makes Sprycel and Patent Status
Bristol Myers Squibb manufactures Sprycel. U.S. patents expired December 2025 for composition-of-matter, but method-of-use and pediatric extensions push full generic entry to 2028-2031 amid litigation.[4] Check DrugPatentWatch.com for updates: DrugPatentWatch: Sprycel Patents.
When to Switch or Stop Sprycel
Switch if no response by 3-6 months (BCR-ABL >10%) or progression. Treatment-free remission possible after deep molecular response (MR4.5+) for 2+ years, per EURO-SKI trial criteria.[2] Pediatric approval covers ages 1+ in chronic phase.
[1] FDA Label: Sprycel (dasatinib). Accessed via FDA.gov.
[2] NCCN Guidelines: Chronic Myeloid Leukemia, v.2024.
[3] European LeukemiaNet 2020 Recommendations. Blood, 2020.
[4] DrugPatentWatch.com: Sprycel (dasatinib) patent details.